Hubei Longxiang Pharmaceutical Tech. Co., ltd. (hereinafter, Longxiang) was founded in 2002. Tianjin Ringpu Biotechnology Co., Ltd. (a listed company: Ringpu Bio, code: 300119) injected capital and held shares in Longxiang in 2008.
Longxiang holds registered capital of 123 million yuan with more than 340 staffs and total assets of 440 million yuan now, and it covers an area of 266,6667 square meters, it has also listed on the New Third Board on March 14, 2017 (NEEQ: 871082).
Longxiang provides veterinary APIs, preparations and pharmaceutical intermediates.
Keep good quality Keep improving
New product
releaseAPIs
Preparation
10%Florfenicol Premix
20% Florfenicol Granule Premix
5%Tylvalosin Tartrate Premix
25%Tylvalosin Tartrate Soluble Powder
30%Florfenicol Soluble Powder
37.5%Tilmicosin Soluble Powder
10%Tilmicosin Phosphate Soluble Powder
10%Doxycycline Hyclate Soluble Powder
6.5%Neomycin Sulfate Soluble Powder
10%Enrofloxacin Soluble Powder
NEWS CENTER
- Company news
- Industry news
- Science and technology leads agricultural innovation and drive development -- longxiang appeared in Agricultural Hi-Tech Expo2020-05-25
- Warm congratulations on longxiang for adding Class II new veterinary drug—Menbutone, which fills the blank of domestic cholagogue for animal use2020-05-25
The approval of menbutone filled in the blank of choleric drugs for animals in China
Keep innovative Keep improving
Longxiang’s products have been recognized by domestic and international customers through technological innovation and registered in more than 30 developed countries and regions such as Germany, Belgium, Japan, Iran, Spain, Mexico and South Korea and so on.Longxiang is the Top 10 veterinary API manufacturers for veterinary APIs in China.
